TTTexas. All of their shareholder updates have been good since they started commercializing Caverstem. Things are coming together nicely. Will this be updates on all of their talking points or will it be a game changer? That’s the big question. Go back and read them all since May 2018.
The only downside has been the cost of commercialization, but revenue is ramping up as we type.